MCID: HPT019
MIFTS: 59

Hepatic Encephalopathy

Categories: Liver diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Hepatic Encephalopathy

MalaCards integrated aliases for Hepatic Encephalopathy:

Name: Hepatic Encephalopathy 12 73 20 36 54 15 70
Portal-Systemic Encephalopathy 12
Encephalopathy, Hepatic 20
Hepatoencephalopathy 20

Classifications:



External Ids:

Disease Ontology 12 DOID:13413
KEGG 36 H01506
ICD9CM 34 572.2
MeSH 44 D006501
NCIt 50 C79596
SNOMED-CT 67 197332007
ICD10 32 K72
UMLS 70 C0019151

Summaries for Hepatic Encephalopathy

GARD : 20 Hepatic encephalopathy is a syndrome observed in some patients with cirrhosis. It is defined as a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction, when other known brain disease has been excluded. Signs and symptoms may be debilitating, and they can begin mildly and gradually, or occur suddenly and severely. They may include personality or mood changes, intellectual impairment, abnormal movements, a depressed level of consciousness, and other symptoms. There are several theories regarding the exact cause, but development of the condition is probably at least partially due to the effect of substances that are toxic to nerve tissue (neurotoxic), which are typically present with liver damage and/or liver disease. Treatment depends upon the severity of mental status changes and upon the certainty of the diagnosis.

MalaCards based summary : Hepatic Encephalopathy, also known as portal-systemic encephalopathy, is related to hepatic coma and acute liver failure. An important gene associated with Hepatic Encephalopathy is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Immune response IL-23 signaling pathway and Circadian entrainment. The drugs Midazolam and Propofol have been mentioned in the context of this disorder. Affiliated tissues include liver, cortex and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A brain disease that is characterized by loss of brain function, the occurrence of confusion, altered level of consciousness, and coma that results when the liver is unable to remove toxins from the blood.

KEGG : 36 Hepatic encephalopathy (HE) is a brain dysfunction caused by liver insufficiency or portal systemic shunting. HE most commonly occurs in decompensated liver cirrhosis and incorporates a spectrum of manifestations that ranges from mild cognitive impairment to coma. Although its pathogenesis is not entirely understood, one of the main factors is thought to be ammonia. Apart from hyperammonemia, various other pathogenic mechanisms, such as the gamma-aminobutyric acid (GABA) theory, the benzodiazepine theory, the manganese theory, and the theory of oxidative/nitrosative stress, have been implicated in the development of HE. The pharmacological treatments that are currently used in clinical practice are directed toward reducing the production and absorption of gut-derived ammonia.

Wikipedia : 73 Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Its onset... more...

Related Diseases for Hepatic Encephalopathy

Diseases related to Hepatic Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 640)
# Related Disease Score Top Affiliating Genes
1 hepatic coma 33.1 TSPO GPT F2 ALB
2 acute liver failure 32.4 TSPO SLC17A5 GPT GC F2
3 hepatorenal syndrome 32.1 IL18 GPT F2 ALB
4 alcoholic liver cirrhosis 31.8 TNF SLC17A5 IL6 GPT F2 ALB
5 liver cirrhosis 31.7 TTR TNF SST SLC17A5 IL6 GPT
6 alcoholic hepatitis 31.6 TNF SLC17A5 IL6 IL18 GPT F2
7 liver disease 31.6 TNF SLC25A13 SLC17A5 IL6 GPT F2
8 varicose veins 31.5 TNF IL6 F2
9 portal hypertension 31.4 TNF SST GPT F2 ALB
10 esophageal varix 31.2 SST GPT F2 ALB
11 peritonitis 31.1 TNF IL6 IL18 F2 ALB
12 brain edema 31.1 SLC25A13 SLC1A2 IL6 HMOX1 GLUL ALB
13 viral hepatitis 30.9 TNF SLC17A5 IL6 GPT F2 ALB
14 fatty liver disease 30.7 TNF SLC25A13 SLC17A5 IL6 GPT
15 active peptic ulcer disease 30.6 SST F2 ALB
16 reye syndrome 30.6 GPT GLUL F2 ALB
17 alcohol dependence 30.6 TSPO TNF SLC1A2 SLC17A5 MAOB MAOA
18 acute kidney failure 30.6 IL18 GPT F2 ALB
19 constipation 30.6 SST S100B NOS1 IL6 GPT ALB
20 cholestasis 30.6 SLC25A13 SLC17A5 GPT F2 ALB
21 non-alcoholic steatohepatitis 30.6 TNF IL6 IL18 GPT ALB
22 meningitis 30.5 TNF IL6 IL18 ALB
23 eclampsia 30.5 TNF F2 ALB
24 sleep disorder 30.5 TNF IL6 ALB
25 hepatitis b 30.4 TNF SLC17A5 IL6 GPT F2 ALB
26 schistosomiasis 30.4 TNF GPT F2 ALB
27 wilson disease 30.4 TNF SLC17A5 IL6 GPT
28 brucellosis 30.4 TNF IL6 IL18
29 brain injury 30.4 S100B IL6 ALB
30 kidney disease 30.4 TTR TNF IL6 IL18 HMOX1 ALB
31 non-a-e hepatitis 30.4 F2 ALB
32 uremia 30.4 TNF IL6 ALB
33 non-alcoholic fatty liver disease 30.3 TNF IL6 IL18 HMOX1 GPT ALB
34 anxiety 30.3 TSPO TNF MAOB MAOA IL6
35 substance abuse 30.3 MAOA IL6 GPT ALB
36 hepatitis e 30.3 TNF GPT F2 ALB
37 diarrhea 30.3 TTR TNF SST IL6 GPT ALB
38 autoimmune hepatitis 30.3 TNF SLC17A5 GPT F2 ALB
39 paracetamol poisoning 30.3 GC F2
40 pulmonary edema 30.3 TNF HMOX1 F2
41 pneumocystosis 30.3 TNF IL6 ALB
42 wernicke encephalopathy 30.2 TSPO SLC1A2 ALB
43 hypothyroidism 30.2 TTR TNF SST GPT ALB
44 pain agnosia 30.2 TNF IL6 ALB
45 agnosia 30.2 TNF IL6 ALB
46 cholecystitis 30.2 GPT F2 ALB
47 appendicitis 30.2 TNF IL6 ALB
48 common cold 30.2 TNF IL6 ALB
49 cellulitis 30.2 TNF IL6 GPT F2 ALB
50 cholangitis 30.2 TNF IL6 GPT F2 ALB

Comorbidity relations with Hepatic Encephalopathy via Phenotypic Disease Network (PDN): (show all 26)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alcohol Use Disorder Alcoholic Hepatitis
Alcoholic Liver Cirrhosis Chronic Kidney Disease
Decubitus Ulcer Deficiency Anemia
Encephalopathy Esophageal Varix
Heart Disease Hepatitis
Hepatocellular Carcinoma Hepatorenal Syndrome
Hypersplenism Liver Disease
Neutropenia Portal Hypertension
Portal Vein Thrombosis Primary Biliary Cholangitis
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Urea Cycle Disorder

Graphical network of the top 20 diseases related to Hepatic Encephalopathy:



Diseases related to Hepatic Encephalopathy

Symptoms & Phenotypes for Hepatic Encephalopathy

MGI Mouse Phenotypes related to Hepatic Encephalopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 F2 GLS GLUL HMOX1 IL18 IL6
2 homeostasis/metabolism MP:0005376 10.28 ALB F2 GC GLUL HMOX1 IL18
3 cellular MP:0005384 10.22 ALB F2 GLS GLUL HMOX1 IL18
4 cardiovascular system MP:0005385 10.21 ALB F2 GLS GLUL HMOX1 IL18
5 mortality/aging MP:0010768 10 ALB F2 GLS GLUL HMOX1 IL18
6 digestive/alimentary MP:0005381 9.97 ALB F2 IL18 IL6 NOS1 SST
7 liver/biliary system MP:0005370 9.86 ALB GLUL HMOX1 IL6 NOS1 SLC25A13
8 nervous system MP:0003631 9.77 F2 GLS GLUL IL18 IL6 MAOA
9 normal MP:0002873 9.28 ALB F2 GLS GLUL NOS1 S100B

Drugs & Therapeutics for Hepatic Encephalopathy

Drugs for Hepatic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Metformin Approved Phase 4 657-24-9 4091 14219
4
Insulin aspart Approved Phase 4 116094-23-6 16132418
5
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
6
Propranolol Approved, Investigational Phase 4 525-66-6 4946
7
Promethazine Approved, Investigational Phase 4 60-87-7 4927
8
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
9
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
10
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 644073 40400
11
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
12
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
13
Ornithine Approved, Nutraceutical Phase 4 70-26-8, 3184-13-2 6262
14
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
15
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
16
Valine Approved, Nutraceutical Phase 4 72-18-4 6287
17 GABA Modulators Phase 4
18 Psychotropic Drugs Phase 4
19 Anesthetics, General Phase 4
20 Anesthetics, Intravenous Phase 4
21 Anti-Anxiety Agents Phase 4
22 Hypoglycemic Agents Phase 4
23 Antioxidants Phase 4
24 Protective Agents Phase 4
25 Neurotransmitter Agents Phase 4
26 N-Methylaspartate Phase 4
27 Vasoconstrictor Agents Phase 4
28 retinol Phase 4
29 Retinol palmitate Phase 4
30 Vasodilator Agents Phase 4
31 Anesthetics Phase 4
32 Hypnotics and Sedatives Phase 4
33 Anti-Arrhythmia Agents Phase 4
34 Adrenergic alpha-Antagonists Phase 4
35 Adrenergic alpha-1 Receptor Antagonists Phase 4
36 Adrenergic Antagonists Phase 4
37 Adrenergic Agents Phase 4
38 Antihypertensive Agents Phase 4
39 Adrenergic beta-Antagonists Phase 4
40 Hormones Phase 4
41 calcium channel blockers Phase 4
42 Calcium, Dietary Phase 4
43 Narcotics Phase 4
44 Analgesics, Opioid Phase 4
45 Analgesics Phase 4
46 Antiemetics Phase 4
47 Histamine Antagonists Phase 4
48
Histamine Phosphate Phase 4 51-74-1 65513
49 Dermatologic Agents Phase 4
50 Anesthetics, Local Phase 4

Interventional clinical trials:

(show top 50) (show all 162)
# Name Status NCT ID Phase Drugs
1 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
2 Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study Unknown status NCT03077217 Phase 4 Rifaximin
3 Randomized Trial Comparing The Efficacy of PEG (Polyethylene Glycol) Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy Unknown status NCT03100513 Phase 4 Lactulose;Polyethylene Glycol
4 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
5 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Unknown status NCT02401490 Phase 4 Human albumin;Placebo
6 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
7 Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
8 Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis Unknown status NCT02470546 Phase 4 Metformin;Placebo
9 LOLA in Hepatic Encephalopathy Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate A Phase iv Randomised Double Blind Placebo- Controlled Trial Completed NCT01847651 Phase 4 LOLA or placebo
10 Effect of Albumine Infusion in the Prevention of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Completed NCT01559519 Phase 4 Albumin
11 Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life Completed NCT00375375 Phase 4 Lactulose
12 The Infusion of L-Ornithine L-aspart is as Effective as Nonabsorbable Disaccharides in the Management of Acute Hepatic Encephalopathy. Completed NCT01041755 Phase 4 L-ornithine-L-aspartate;Lactose
13 Rifaximin and Its Microbial Resistance as a Secondary Prophylaxis of Hepatic Encephalopathy in Patients With HCV Related Cirrhosis Completed NCT04736836 Phase 4 Rifaximin
14 A Multicenter, Randomized, Open-Label, Active-Controlled, Trial to Evaluate the Safety and Efficacy of Rifaximin 550 mg With and Without Lactulose in Subjects With a History of Recurrent Overt Hepatic Encephalopathy Completed NCT01842581 Phase 4 Rifaximin;Lactulose
15 Efficacy of Combined Oral L-ornithine-L-aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy Completed NCT00740142 Phase 4 L-ornithine-L-aspartate and lactulose;placebo and lactulose
16 Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleeding in Cirrhotic Patients Completed NCT02158182 Phase 4 Lactulose;L-ornithine L-aspartate;Rifaximin;Placebo
17 Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy. Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
18 Effect of the Proteins of the Diet in Patients With Cirrhosis and a Prior Episode of Hepatic Encephalopathy. A Randomized Study Completed NCT00955500 Phase 4
19 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
20 Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers Completed NCT01846455 Phase 4 2.0mg Buprenorphine/0.5mg Naloxone;Promethazine
21 Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo
22 Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial Completed NCT01722578 Phase 4 L-ornithine L-aspartate;Placebo
23 A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy Completed NCT02019784 Phase 4 Rifaximin-α;Placebo Oral Tablet
24 Therapeutic Efficacy of Oral PEG3350 Plus Lactulose Versus Lactulose Alone in Patients of Acute on Chronic Liver Failure With Overt Hepatic Encephalopathy: A Single Blind Prospective Randomized Controlled Study Recruiting NCT03987893 Phase 4 PEG-3350 with Electolytes;Lactulose
25 Effect of Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Liver Cirrhosis; a Randomized Clinical Trial (PEGHE Trial) Recruiting NCT04436601 Phase 4 Polyethylene Glycols;Lactulose
26 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy Recruiting NCT01846663 Phase 4 Placebo;Rifaximin
27 Prevention of Hepatic Encephalopathy by Administration of Rifaximin and Lactulose in Patients With Liver Cirrhosis Undergoing TIPS Placement: a Multi-centre Randomized, Double Blind, Placebo Controlled Trial. Recruiting NCT04073290 Phase 4 Rifaximin 550 milligram Oral Tablet [XIFAXAN];Placebo oral tablet;Lactulose 667 milligram/milliliter Oral Solution
28 Effects of Intrathoracic Pressure Regulation Therapy in Patients With Elevated Intracranial Pressure Due to Brain Injury or Intracranial Pathology Terminated NCT01824589 Phase 4
29 Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin. Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
30 Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease Withdrawn NCT01654939 Phase 4 Rifaximin
31 A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy Unknown status NCT02464124 Phase 2, Phase 3 Nitazoxanide;Lactulose
32 Minimal Hepatic Encephalopathy in Pre-hepatic Portal Hypertension Due to Portal Vein Thrombosis in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study. Unknown status NCT01798329 Phase 3
33 Randomized Double Blind Placebo Controlled Trial of Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage Unknown status NCT00553423 Phase 3 Lactulose;Placebo
34 A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen. Completed NCT00248625 Phase 3 N-acetylcysteine;Placebo
35 13C-Methacetin Breath Test for the Prediction of Outcome in in Acute Liver Injury or Acute Liver Failure Completed NCT02786836 Phase 2, Phase 3 13C-Methacetin
36 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy Completed NCT00298038 Phase 3 Rifaximin;Placebo
37 Efficacy of a Three Days' Infusion of L-Ornithine-L-Aspartate as an Adjuvant Therapy in Cirrhotic Patients With Overt Hepatic Encephalopathy: A Placebo Controlled Study Completed NCT00433368 Phase 3 L-Ornithine L-Aspartate
38 Secondary Prophylaxis of Hepatic Encephalopathy: A Double Blind, Randomized, Placebo Controlled Study With Supplementation With a Probiotic Preparation Completed NCT01110447 Phase 2, Phase 3 VSL#3
39 A Multi-Center, Open-Label Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 mg BID in Subjects With a History of Hepatic Encephalopathy Completed NCT00686920 Phase 3 Rifaximin
40 Health Related Quality of Life in Patient With Chronic Liver Disease and Effect of Probiotics in the Treatment of MHE and Health Related Quality of Life Completed NCT01008293 Phase 2, Phase 3 VSL#3;Lactulose
41 Effects of Tolvaptan on Cognitive Function, Brain Metabolism and Quality of Life in Hyponatremic Cirrhotics With Hepatic Encephalopathy: A Prospective Clinical Trial Completed NCT01556646 Phase 3 Tolvaptan
42 Acetyl-L-Carnitine Reduces Perceived Work Stress and Improves Work Ability and Work Performance in Hepatic Encephalopathy Completed NCT02173132 Phase 3 Acetyl-L-carnitine
43 Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy Recruiting NCT04161053 Phase 3 Rifaximin;Nitazoxanide
44 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of MNK6105 (an Intravenous Formulation of L-Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Hyperammonemia Associated With an Episode of Hepatic Encephalopathy Not yet recruiting NCT04128462 Phase 3 MNK-6105;Placebo;Standard of Care
45 Evaluation of the Therapeutic Effect of Rifaximin on Covert Hepatic Encephalopathy With Underlying Small Intestinal Bacterial Overgrowth and Gastrointestinal Dysmotility in Liver Cirrhosis Patients Not yet recruiting NCT04244877 Phase 3 Rifaximin
46 A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure Terminated NCT01829347 Phase 3
47 RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial Terminated NCT00364689 Phase 3 Rifaximin;Lactulose
48 A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure Withdrawn NCT02086825 Phase 3 Rifaximin;Lactulose
49 The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Phase A: Breath Testing and Colonic Transit in Hepatic Encephalopathy. Phase B: A Randomized Double Blind, Placebo Controlled Trial of Rifaximin for Hepatic Encephalopathy Unknown status NCT00281502 Phase 2 Rifaximin (drug)
50 Molecular Adsorbent Recirculating System (MARS®) for the Treatment of Patients With Hypoxic Hepatitis - a Prospective Randomized Controlled Clinical Study Unknown status NCT01690845 Phase 2

Search NIH Clinical Center for Hepatic Encephalopathy

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Kanamycin Sulfate
Lactulose
NEOMYCIN SO4 PWDR

Genetic Tests for Hepatic Encephalopathy

Anatomical Context for Hepatic Encephalopathy

MalaCards organs/tissues related to Hepatic Encephalopathy:

40
Liver, Cortex, Brain, Cerebellum, Colon, Globus Pallidus, Neutrophil

Publications for Hepatic Encephalopathy

Articles related to Hepatic Encephalopathy:

(show top 50) (show all 8455)
# Title Authors PMID Year
1
Conventional diet therapy for hyperammonemia is risky in the treatment of hepatic encephalopathy associated with citrin deficiency. 54 61
20118603 2010
2
Outcome of patients with primary hepatic venous obstruction treated with anticoagulants alone. 54 61
20373079 2010
3
[A simple scoring system to evaluate the severity of acute-on-chronic liver failure in hepatitis B]. 54 61
20193566 2009
4
[Analysis of prognostic factors for patients with acute-on-chronic liver failure]. 54 61
19719920 2009
5
Retrospective study of the clinical profile and prognostic indicators in patients of alcoholic liver disease admitted to a tertiary care teaching hospital in Western Nepal. 61 54
19636178 2009
6
[Anemia in hospitalized patients with cirrhosis: prevalence, clinical relevance and predictive factors]. 61 54
19663083 2009
7
Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. 54 61
19267864 2009
8
Natural endogenous ligands for benzodiazepine receptors in hepatic encephalopathy. 54 61
19082698 2009
9
Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. 61 54
19175915 2009
10
In-hospital mortality in spontaneous bacterial peritonitis: a new predictive model. 61 54
18941414 2008
11
[Clinical outcomes and predictive factors of spontaneous survival in patients with fulminant hepatitis A]. 61 54
19119242 2008
12
Albumin dialysis has a favorable effect on amino acid profile in hepatic encephalopathy. 54 61
18773287 2008
13
[Natural history of primary biliary cirrhosis]. 61 54
18928750 2008
14
Gc-globulin in liver disease. 54 61
19232164 2008
15
Which is the best way to analyze the efficacy of albumin dialysis in hepatic encephalopathy? 54 61
18666248 2008
16
Adjuvant therapeutic plasma exchange in liver failure: assessments of clinical and laboratory parameters. 61 54
18344887 2008
17
Prognostic factors for chronic severe hepatitis and construction of a prognostic model. 61 54
18234637 2008
18
Acute liver failure in Lithuania. 61 54
18695350 2008
19
Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. 54 61
17975845 2007
20
Aquaporin-4 in hepatic encephalopathy. 54 61
17879149 2007
21
[Analysis of survival rate and risk factors of liver retransplantation]. 61 54
18005577 2007
22
Liver support systems. 54 61
17464150 2007
23
Drug insight: the role of albumin in the management of chronic liver disease. 54 61
17203088 2007
24
Molecular adsorbent recirculating system dialysis in patients with acute liver failure who are assessed for liver transplantation. 54 61
16941171 2006
25
Peripheral benzodiazepine receptors in the brain of cirrhosis patients with manifest hepatic encephalopathy. 54 61
16550382 2006
26
[Observation on hybrid bioartificial liver support systems in treating chronic severe hepatitis: a study of 60 cases]. 54 61
16556417 2006
27
Prediction of hepatic encephalopathy development in patients with severe acute hepatitis. 61 54
16534681 2006
28
Role of phosphate-activated glutaminase in the pathogenesis of hepatic encephalopathy. 61 54
16382342 2005
29
Role of endogenous benzodiazepine ligands and their GABA-A--associated receptors in hepatic encephalopathy. 61 54
16382352 2005
30
[Preliminary study on the effects of an artificial liver support system in the treatment of medicamentous liver insufficiency]. 61 54
16313729 2005
31
[Analysis of prognostic factors of and to establish a predictive model for patients with chronic severe hepatitis]. 61 54
16248942 2005
32
Successful treatment of an adult with Amanita phalloides-induced fulminant liver failure with molecular adsorbent recirculating system (MARS). 54 61
16200238 2005
33
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. 54 61
16123966 2005
34
Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. 54 61
15985009 2005
35
Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United kingdom. 61 54
15861019 2005
36
[Analysis on prognostic factors of liver failure in children]. 61 54
16201463 2005
37
The impact of total plasma exchange on early allograft dysfunction. 61 54
15621091 2004
38
Clinical and laboratory features of spontaneous bacterial peritonitis. 54 61
15626058 2004
39
Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. 54 61
15246207 2004
40
Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. 54 61
14678008 2004
41
Benzodiazepine receptor antagonists for hepatic encephalopathy. 61 54
15106178 2004
42
Clinical significance and prediction factors of gastric varices in patients with hepatocellular carcinoma. 61 54
14571795 2003
43
Low serum total thyroxine and free triiodothyronine in patients with hepatic encephalopathy due to non-alcoholic cirrhosis. 54 61
12811678 2003
44
Renal impairment after spontaneous bacterial peritonitis: incidence and prognosis. 54 61
12677269 2003
45
A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. 54 61
12639207 2003
46
Discriminant function for prognostic indexes and probability of death in chronic severe hepatitis B. 61 54
14564632 2003
47
Successful use of Molecular Absorbent Regenerating System (MARS) dialysis for the treatment of fulminant hepatic failure in children accidentally poisoned by toxic mushroom ingestion. 61 54
12950957 2003
48
Region selective alterations of soluble guanylate cyclase content and modulation in brain of cirrhotic patients. 61 54
12395325 2002
49
Treatment of liver failure in rats with end-stage cirrhosis by transplantation of immortalized hepatocytes. 54 61
12143047 2002
50
Glutamine synthetase in brain: effect of ammonia. 54 61
12020613 2002

Variations for Hepatic Encephalopathy

Expression for Hepatic Encephalopathy

LifeMap Discovery
Genes differentially expressed in tissues of Hepatic Encephalopathy patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 PSPH phosphoserine phosphatase Brain - 4.35 0.000
Search GEO for disease gene expression data for Hepatic Encephalopathy.

Pathways for Hepatic Encephalopathy

Pathways related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.43 TNF NOS1 IL6 IL18 F2
2
Show member pathways
12.41 SLC1A2 NOS1 MAOB MAOA GLUL GLS
3
Show member pathways
12.23 TNF IL6 F2 ALB
4 12.05 TNF SST MAOA IL6
5
Show member pathways
11.66 TNF IL6 IL18
6 11.56 TNF IL6 HMOX1
7
Show member pathways
11.52 NOS1 MAOB MAOA
8 11.5 TNF IL6 IL18
9 11.43 TNF IL6 IL18
10 11.41 TNF IL6 IL18
11 11.41 TNF MAOA IL6 IL18 HMOX1
12 11.34 TTR F2 ALB
13
Show member pathways
11.32 TNF NOS1 MAOA
14
Show member pathways
11.27 GPT GLUL GLS
15 11.21 TNF SLC1A2 NOS1
16 11.18 GPT GLUL GLS
17 11.15 TNF IL6 IL18
18 11.09 TNF IL6 HMOX1
19 11 TNF IL6 IL18
20 10.61 TNF IL6 HMOX1
21
Show member pathways
10.49 SLC1A2 GLUL
22
Show member pathways
10.36 NOS1 GPT GLUL GLS

GO Terms for Hepatic Encephalopathy

Cellular components related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 TTR TNF SST S100B IL6 IL18

Biological processes related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.85 TTR IL6 F2 ALB
2 response to drug GO:0042493 9.8 TSPO SST SLC1A2 MAOB HMOX1
3 cytokine-mediated signaling pathway GO:0019221 9.77 TNF MAOA IL6 IL18 HMOX1
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 TNF IL6 IL18
5 cellular amino acid biosynthetic process GO:0008652 9.63 GPT GLUL GLS
6 positive regulation of chemokine production GO:0032722 9.61 TNF IL6 HMOX1
7 neurotransmitter catabolic process GO:0042135 9.56 MAOB MAOA
8 dopamine catabolic process GO:0042420 9.52 MAOB MAOA
9 negative regulation of lipid storage GO:0010888 9.51 TNF IL6
10 positive regulation of JAK-STAT cascade GO:0046427 9.5 TNF IL6 F2
11 L-aspartate transmembrane transport GO:0070778 9.49 SLC25A13 SLC1A2
12 vascular endothelial growth factor production GO:0010573 9.48 TNF IL6
13 transport GO:0006810 9.43 SLC25A13 GC ALB
14 positive regulation of glial cell proliferation GO:0060252 9.33 TSPO TNF IL6
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.26 TNF IL6 IL18 HMOX1
16 positive regulation of neuroinflammatory response GO:0150078 8.8 TNF IL6 IL18

Molecular functions related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.56 TTR TNF SLC25A13 S100B MAOB HMOX1
2 primary amine oxidase activity GO:0008131 8.62 MAOB MAOA

Sources for Hepatic Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....